Other languages Lunit Inc.

Equities

A328130

KR7328130000

End-of-day quote Korea S.E. Other stock markets 03:30:00 24/05/2024 am IST			5-day change	1st Jan Change
56,900 ^KRW	-1.04%		+4.02%	-30.53%

24/05	Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response	CI
23/05	Lunit Acquires New Zealand's Volpara Health Technologies	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response	24/05
Volpara to Delist After Court Approves Acquisition by Lunit	03/05
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover	12/04
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals	08/04
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO	26/03
Lunit Announces Two Commercial Deals Signal its Expansion in Europe	18/03
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region	11/03
Lunit Announces Three-Year Supply Contract with Samsung Electronics	16/01
Lunit Inc. Partners with NTT DATA Singapore to Introduce Lunit Insight CXR to Singapore's Public Healthcare System	30/11
Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology	27/11
Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America	20/11
Lunit Inc. Receives U.S. Food and Drug Administration 510(K) Clearance for its 3D Breast Tomosynthesis Ai Solution, Lunit Insight DBT	14/11
Lunit Expands Reach of Its AI-Powered Chest Screening Solution to Global Military Health Institutions	09/11
Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes	01/11
Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy	27/23/27
New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023	16/23/16
Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer	01/23/01
Blackford and Lunit Inc Announce Partnership to Enhance Chest and Breast Ai Solution Offering	27/23/27
Lunit Accelerates Expansion Across Middle East by Bringing AI Solution to Dr. Sulaiman Al Habib Medical Group	26/23/26
Lunit Makes Full-Fledged Entry into the Middle East with Participation in 'Saudi Vision 2030' Healthcare Transformation Project	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lunit Inc.

Equities

A328130

KR7328130000

Other languages

Filters